Memantine Augmentation in Obsessive-Compulsive Disorder

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00264238
First received: December 9, 2005
Last updated: April 8, 2009
Last verified: April 2009

December 9, 2005
April 8, 2009
January 2006
June 2008   (final data collection date for primary outcome measure)
Y-BOCS score at final study visit
Same as current
Complete list of historical versions of study NCT00264238 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Memantine Augmentation in Obsessive-Compulsive Disorder
An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication. Memantine is not FDA approved for OCD, but is approved for the treatment of Alzheimer's Disease. Memantine appears to work by regulating the activity of glutamate, one of the brain's specialized messenger chemicals, which may play a role in OCD. All patients in the study will receive memantine; no one will receive placebo.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Obsessive-Compulsive Disorder
Drug: Memantine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
June 2008
June 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • at least 18 years of age
  • suffering from OCD
  • Y-BOCS score of 18 or greater
  • taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria:- diagnosed with a mental disorder other than OCD

  • taking tiagabine or pregabalin
  • having had a previous trial of memantine
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00264238
SUSPO34313
Not Provided
ohn J Barry, Principal Investigator, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: John J Barry Stanford University
Stanford University
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP